Income Statement (TTM)
Cartesian Therapeutics, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2021 12-31 |
2022 12-31 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 85 | 111 | 127 | 26 | 26 | 54 | 48 | 39 | 34 | 1 |
| Change (%) | 30.21 | 15.08 | -79.60 | -0.38 | 108.84 | -11.39 | -18.83 | -12.18 | -97.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 69 | 72 | 117 | 66 | 48 | 31 | 29 | 45 | 45 | 47 |
| Change (%) | 5.30 | 60.98 | -43.65 | -27.28 | -35.62 | -5.21 | 54.10 | 1.25 | 2.27 | |
| % of Revenue | 80.79 | 65.34 | 91.40 | 252.50 | 184.31 | 56.82 | 60.79 | 115.40 | 133.05 | 4,532.36 |
| Gross Operating Profit | 16 | 38 | 11 | -40 | -22 | 23 | 19 | -6 | -11 | -45 |
| Change (%) | 134.99 | -71.44 | -461.56 | -44.92 | -206.95 | -19.53 | -131.88 | 88.50 | 302.62 | |
| % of Revenue | 19.21 | 34.66 | 8.60 | -152.50 | -84.31 | 43.18 | 39.21 | -15.40 | -33.05 | -4,432.36 |
| SG&A | 21 | 24 | 41 | 35 | 38 | 39 | 39 | 30 | 29 | 29 |
| Change (%) | 13.97 | 72.69 | -15.67 | 9.08 | 2.43 | -0.13 | -23.85 | -1.81 | 0.73 | |
| % of Revenue | 24.61 | 21.54 | 32.32 | 133.63 | 146.32 | 71.77 | 80.89 | 75.88 | 84.84 | 2,846.39 |
| R&D | 9 | 21 | 21 | 5 | 6 | |||||
| Change (%) | 134.66 | 0.00 | 25.67 | |||||||
| % of Revenue | 34.07 | 38.28 | 43.20 | 13.38 | 560.14 | |||||
| OpEx | 90 | 96 | 158 | 100 | 94 | 90 | 89 | 74 | 79 | 81 |
| Change (%) | 7.32 | 63.88 | -36.34 | -5.91 | -4.44 | -1.83 | -16.02 | 6.18 | 3.06 | |
| % of Revenue | 105.40 | 86.88 | 123.72 | 386.13 | 364.70 | 166.87 | 184.88 | 191.28 | 231.27 | 7,938.89 |
| Operating Income | -5 | 15 | -30 | -74 | -69 | -36 | -41 | -36 | -45 | -80 |
| Change (%) | -416.25 | -308.00 | 146.06 | -7.84 | -47.24 | 12.47 | -12.71 | 26.30 | 79.29 | |
| % of Revenue | -5.40 | 13.12 | -23.72 | -286.13 | -264.70 | -66.87 | -84.88 | -91.28 | -131.27 | -7,838.89 |
| Interest Expense | -3 | -3 | -6 | -3 | -2 | -1 | 0 | |||
| Change (%) | 6.58 | 93.47 | -51.69 | -28.52 | -37.14 | -100.00 | ||||
| % of Revenue | -3.34 | -2.74 | -4.60 | -10.89 | -7.82 | -2.35 | 0.00 | |||
| Net Income | -26 | 35 | -1 | -220 | -255 | -230 | -245 | -77 | -38 | -36 |
| Change (%) | -237.73 | -104.20 | 14,675.39 | 16.00 | -9.90 | 6.61 | -68.38 | -50.52 | -5.35 | |
| % of Revenue | -30.19 | 31.94 | -1.17 | -844.91 | -983.83 | -424.47 | -510.72 | -198.97 | -112.11 | -3,534.11 |
Source: Capital IQ
